Showing 18,021 - 18,040 results of 45,793 for search '(( 5 ((step decrease) OR (mean decrease)) ) OR ( 50 ((we decrease) OR (a decrease)) ))', query time: 1.36s Refine Results
  1. 18021

    Use of a Novel Chagas Urine Nanoparticle Test (Chunap) for Diagnosis of Congenital Chagas Disease by Yagahira E. Castro-Sesquen (284439)

    Published 2014
    “…The nanoparticles concentrate <i>T. cruzi</i> antigens by 100 fold (western blot detection limit decreased from 50 ng/ml to 0.5 ng/ml). The sensitivity of Chunap in a single specimen at one month of age was 91.3% (21/23, 95% CI: 71.92%–98.68%), comparable to PCR in two specimens at 0 and 1 month (91.3%) and significantly higher than microscopy in two specimens (34.8%, 95% CI: 16.42%–57.26%). …”
  2. 18022

    Data_Sheet_1_Mindfulness Training for Primary Care for Portuguese-Speaking Immigrants: A Pilot Study.docx by Marcelo Trombka (11411288)

    Published 2021
    “…All survey finishers would recommend the program to a friend, found the program helpful, and rated the overall program as “very good” or “excellent,” and 93% would participate again, with satisfaction mean scores between 4.6 and 5 (Likert scale 0–5). …”
  3. 18023

    Rescue the Failed Half-ZFN by a Sensitive Mammalian Cell-Based Luciferase Reporter System by Weifeng Zhang (134361)

    Published 2012
    “…Lastly, site-specific genome editing by hPGRN ZFNs generated by this system was confirmed by sequencing, and the PGRN knock-out cell line showed significantly decreased cell growth compared with the control. Our system will provide a valuable tool for further optimizing the nucleases with regard to specificity and cytotoxicity.…”
  4. 18024
  5. 18025
  6. 18026

    Statin Effects on Aggression: Results from the UCSD Statin Study, a Randomized Control Trial by Beatrice A. Golomb (140574)

    Published 2015
    “…</p><p>Trial Registration</p><p>Clinicaltrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT00330980" target="_blank">NCT00330980</a></p></div>…”
  7. 18027

    Table_2_Genotypes of Pain and Analgesia in a Randomized Trial of Irritable Bowel Syndrome.XLSX by Jan Vollert (5099921)

    Published 2022
    “…Background<p>Irritable bowel syndrome (IBS) is a highly prevalent chronic pain disorder with multiple underlying mechanisms and few treatments that have been demonstrated to be effective in placebo controlled trials. …”
  8. 18028

    Table_1_Genotypes of Pain and Analgesia in a Randomized Trial of Irritable Bowel Syndrome.xlsx by Jan Vollert (5099921)

    Published 2022
    “…Background<p>Irritable bowel syndrome (IBS) is a highly prevalent chronic pain disorder with multiple underlying mechanisms and few treatments that have been demonstrated to be effective in placebo controlled trials. …”
  9. 18029

    Neutralization of point mutants of B.1.351 and D614G spike-pseudotyped lentiviral particles by convalescent plasmas from B.1.351 and early 2020-infected individuals. by Allison J. Greaney (11046384)

    Published 2022
    “…<b>(B)</b> The fold-decrease in neutralization for samples shown in <b><a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1010248#ppat.1010248.g005" target="_blank">Fig 5</a></b>, with the addition of previously measured neutralization by samples from 6 early 2020 convalescent individuals collected approximately 100 days post-symptom onset [<a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1010248#ppat.1010248.ref038" target="_blank">38</a>]. …”
  10. 18030

    Data_Sheet_1_Metabolomics of Cerebrospinal Fluid in Multiple Sclerosis Compared With Healthy Controls: A Pilot Study.PDF by Michal Židó (12641944)

    Published 2022
    “…During the targeted analysis, a significant decrease in arginine and histidine and a less significant decrease in the levels of asparagine, leucine/isoleucine, and tryptophan, together with a significant increase of palmitic acid in the patient group, were found.…”
  11. 18031

    A reduction in brain mass and cortical volume seen in the adult <i>Cln6<sup>nclf</sup></i> mouse. by Jeremy P. Morgan (479017)

    Published 2013
    “…<p>Brain mass was assessed in the <i>Cln6<sup>nclf</sup></i>, as a decrease in brain mass is often seen in vLINCL patients. …”
  12. 18032
  13. 18033
  14. 18034

    Efficacy of Rifampin Plus Clofazimine in a Murine Model of <i>Mycobacterium ulcerans</i> Disease by Paul J. Converse (227430)

    Published 2015
    “…Footpad swelling declined comparably with all of the combination regimens, as did the levels of detectable mycolactone A/B. In mice treated for only 6 weeks and followed up for 24 weeks, there were no relapses in RIF+STR treated mice, one (5%) relapse in RIF+CFZ-treated mice, but >50% in RIF+CLR treated mice. …”
  15. 18035

    Frequency trajectories of iSNVs that fluctuated (Top) and their positions on the genome (Bottom) (patients A-I). by Lele Zhao (532080)

    Published 2025
    “…<p>The inclusion criterion was iSNVs that changed from below 50% at Baseline (i.e., 0 days post baseline), to above 50% at PT12 (12 weeks post treatment), and decreased to below 50% at PT24 (24 weeks post treatment). …”
  16. 18036

    Adverse event list. by Stefan Halbherr (21353882)

    Published 2025
    “…</p><p>Non-motor symptoms of PD, motor parkinsonian signs off medication, and quality of life improved significantly during the treatment phase, including the MDS-UPDRS total score (mean decrease −11.09; 95% Confidence Interval [CI]; −18, −4.1; <i>p</i> = 0.006), the Parkinson’s disease Questionnaire-39 (PDQ-39) summary index (mean decrease −2.91; 95% CI; −4.4, −1.4; <i>p</i> = 0.005), and the Non-Motor Symptoms Questionnaire (NMS-Quest) (mean decrease −4.27; 95% CI; −6.5, −2.1; <i>p</i> = 0.009). …”
  17. 18037

    Patient characteristics. by Stefan Halbherr (21353882)

    Published 2025
    “…</p><p>Non-motor symptoms of PD, motor parkinsonian signs off medication, and quality of life improved significantly during the treatment phase, including the MDS-UPDRS total score (mean decrease −11.09; 95% Confidence Interval [CI]; −18, −4.1; <i>p</i> = 0.006), the Parkinson’s disease Questionnaire-39 (PDQ-39) summary index (mean decrease −2.91; 95% CI; −4.4, −1.4; <i>p</i> = 0.005), and the Non-Motor Symptoms Questionnaire (NMS-Quest) (mean decrease −4.27; 95% CI; −6.5, −2.1; <i>p</i> = 0.009). …”
  18. 18038

    Table_1_A Time-Dose Response Model to Assess Diuron-Induced Photosynthesis Inhibition in Freshwater Biofilms.DOCX by Soizic Morin (597578)

    Published 2018
    “…We found a rapid decrease in photosynthetic efficiency: t<sub>1/2</sub> values were dose-dependent and ranged from < 30 s (highest concentration of exposure) to 7′20<sup>′′</sup> (lowest concentration). …”
  19. 18039

    Evaluation of the Association between the AC3 Genetic Polymorphisms and Obesity in a Chinese Han Population by Hairu Wang (238131)

    Published 2010
    “…</p><h3>Methodology/Principal Findings</h3><p>In the present study, we evaluated the association between the AC3 genetic polymorphisms and obesity in a Han Chinese population. …”
  20. 18040

    Table 1_Survival assessment in extremely preterm neonates in a middle-income setting.docx by Maria J. Rodriguez-Sibaja (17456689)

    Published 2025
    “…This study aimed to describe the hospital discharge survival of extremely preterm infants born in a middle-income setting. As a secondary objective, we assessed the neonatal morbidity associated with this group.…”